Linked Life Data

12950266

Source:http://linkedlifedata.com/resource/pubmed/id/12950266

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12950266rdf:typepubmed:Citationlld:pubmed
pubmed-article:12950266lifeskim:mentionsumls-concept:C0331123lld:lifeskim
pubmed-article:12950266lifeskim:mentionsumls-concept:C0041348lld:lifeskim
pubmed-article:12950266lifeskim:mentionsumls-concept:C1514562lld:lifeskim
pubmed-article:12950266lifeskim:mentionsumls-concept:C1883221lld:lifeskim
pubmed-article:12950266lifeskim:mentionsumls-concept:C1145667lld:lifeskim
pubmed-article:12950266lifeskim:mentionsumls-concept:C0008550lld:lifeskim
pubmed-article:12950266lifeskim:mentionsumls-concept:C0170214lld:lifeskim
pubmed-article:12950266lifeskim:mentionsumls-concept:C1883204lld:lifeskim
pubmed-article:12950266lifeskim:mentionsumls-concept:C1880389lld:lifeskim
pubmed-article:12950266pubmed:issue18lld:pubmed
pubmed-article:12950266pubmed:dateCreated2003-9-2lld:pubmed
pubmed-article:12950266pubmed:abstractTextThe antimitotic depsipeptide dolastatin 15 was radiolabeled with tritium in its amino-terminal dolavaline residue. Dolastatin 15, although potently cytotoxic, is a relatively weak inhibitor of tubulin assembly and does not inhibit the binding of any other ligand to tubulin. The only methodology found to demonstrate an interaction between the depsipeptide and tubulin was Hummel-Dreyer equilibrium chromatography on Sephadex G-50 superfine. The average apparent Kd value obtained in these studies was about 30 microM, with no difference observed when column size or tubulin concentration was varied. This relatively high dissociation constant is consistent with the apparent weak interaction of dolastatin 15 with tubulin demonstrated indirectly in the assembly assay. We attempted to gain insight into the binding site for dolastatin 15 on tubulin by studying inhibitory effects of other drugs when the gel filtration column was equilibrated with both [3H]dolastatin 15 and a second, nonradiolabeled drug. No inhibition was detected with either the colchicine site agent combretastatin A-4 or with an analog of the antimitotic marine peptide diazonamide A (both the analog and diazonamide A are potent inhibitors of tubulin assembly). Weak inhibition was observed with cemadotin, a structural analog of dolastatin 15, and with the depsipeptide cryptophycin 1. Moderate inhibition occurred with vinblastine and vincristine, and strong inhibition with maytansine, halichondrin B, and the peptides dolastatin 10 and phomopsin A. These observations suggest that the binding site(s) for peptide and depsipeptide antimitotic drugs may consist of a series of overlapping domains rather than a well-defined locus on the surface of beta-tubulin.lld:pubmed
pubmed-article:12950266pubmed:languageenglld:pubmed
pubmed-article:12950266pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12950266pubmed:citationSubsetIMlld:pubmed
pubmed-article:12950266pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12950266pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12950266pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12950266pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12950266pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12950266pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12950266pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12950266pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12950266pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12950266pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12950266pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12950266pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12950266pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12950266pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12950266pubmed:statusMEDLINElld:pubmed
pubmed-article:12950266pubmed:monthSeplld:pubmed
pubmed-article:12950266pubmed:issn0014-2956lld:pubmed
pubmed-article:12950266pubmed:authorpubmed-author:PettitGeorge...lld:pubmed
pubmed-article:12950266pubmed:authorpubmed-author:HamelErnestElld:pubmed
pubmed-article:12950266pubmed:authorpubmed-author:Cruz-Monserra...lld:pubmed
pubmed-article:12950266pubmed:authorpubmed-author:MullaneyJeffr...lld:pubmed
pubmed-article:12950266pubmed:authorpubmed-author:HarranPatrick...lld:pubmed
pubmed-article:12950266pubmed:issnTypePrintlld:pubmed
pubmed-article:12950266pubmed:volume270lld:pubmed
pubmed-article:12950266pubmed:ownerNLMlld:pubmed
pubmed-article:12950266pubmed:authorsCompleteYlld:pubmed
pubmed-article:12950266pubmed:pagination3822-8lld:pubmed
pubmed-article:12950266pubmed:dateRevised2007-7-23lld:pubmed
pubmed-article:12950266pubmed:meshHeadingpubmed-meshheading:12950266...lld:pubmed
pubmed-article:12950266pubmed:meshHeadingpubmed-meshheading:12950266...lld:pubmed
pubmed-article:12950266pubmed:meshHeadingpubmed-meshheading:12950266...lld:pubmed
pubmed-article:12950266pubmed:meshHeadingpubmed-meshheading:12950266...lld:pubmed
pubmed-article:12950266pubmed:meshHeadingpubmed-meshheading:12950266...lld:pubmed
pubmed-article:12950266pubmed:meshHeadingpubmed-meshheading:12950266...lld:pubmed
pubmed-article:12950266pubmed:meshHeadingpubmed-meshheading:12950266...lld:pubmed
pubmed-article:12950266pubmed:meshHeadingpubmed-meshheading:12950266...lld:pubmed
pubmed-article:12950266pubmed:meshHeadingpubmed-meshheading:12950266...lld:pubmed
pubmed-article:12950266pubmed:meshHeadingpubmed-meshheading:12950266...lld:pubmed
pubmed-article:12950266pubmed:meshHeadingpubmed-meshheading:12950266...lld:pubmed
pubmed-article:12950266pubmed:meshHeadingpubmed-meshheading:12950266...lld:pubmed
pubmed-article:12950266pubmed:meshHeadingpubmed-meshheading:12950266...lld:pubmed
pubmed-article:12950266pubmed:meshHeadingpubmed-meshheading:12950266...lld:pubmed
pubmed-article:12950266pubmed:meshHeadingpubmed-meshheading:12950266...lld:pubmed
pubmed-article:12950266pubmed:meshHeadingpubmed-meshheading:12950266...lld:pubmed
pubmed-article:12950266pubmed:meshHeadingpubmed-meshheading:12950266...lld:pubmed
pubmed-article:12950266pubmed:year2003lld:pubmed
pubmed-article:12950266pubmed:articleTitleDolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography.lld:pubmed
pubmed-article:12950266pubmed:affiliationNational Cancer Institute at Frederick, National Institutes of Health, Frederick, MD 21702, USA.lld:pubmed
pubmed-article:12950266pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12950266lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12950266lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12950266lld:pubmed